Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CERINTA vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); enhances serotonergic neurotransmission by inhibiting serotonin reuptake at the presynaptic neuron.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Premenstrual dysphoric disorder
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
50 mg orally twice daily
400 mg orally once daily with food.
Terminal elimination half-life is 12 hours (range 10–14 h) in adults; prolonged to 24–30 h in severe renal impairment (Cr Cl <30 m L/min).
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Primarily hepatic via CYP2D6 and CYP3A4; active metabolites include N-desmethylcitalopram.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Renal (70% unchanged) and fecal (25% as metabolites); biliary excretion minimal (<5%).
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
98% bound to albumin and alpha-1-acid glycoprotein.
98% bound to albumin
Vd = 0.5–0.8 L/kg, indicating distribution into total body water and some tissue binding.
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral: 75–85% (first-pass metabolism reduces bioavailability from 90% to 75–85%).
Oral: 85-90%; IM: 95-100%
GFR ≥60 m L/min: No adjustment. GFR 30-59 m L/min: Reduce dose to 25 mg twice daily. GFR <30 m L/min: Not recommended.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 25 mg twice daily. Child-Pugh C: Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Safety and efficacy not established in pediatric patients.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
No specific dose adjustment; use caution due to increased risk of adverse effects.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Serotonin syndrome,QT prolongation,Hyponatremia,Activation of mania/hypomania,Seizure risk,Angle-closure glaucoma
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Concomitant use with MAOIs or within 14 days of MAOI discontinuation,Concomitant use with pimozide,Known hypersensitivity to cerinta
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
Take with food to improve absorption and reduce GI side effects. Avoid grapefruit, grapefruit juice, and Seville oranges as they are strong CYP3A4 inhibitors and can increase ceritinib levels.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
Cerinta is contraindicated in pregnancy. First trimester: High risk of neural tube defects and cardiac malformations. Second and third trimesters: Risk of oligohydramnios, fetal renal dysfunction, and skull ossification delay.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Contraindicated. Cerinta excreted in human milk; M/P ratio not established. Potential for infant nephrotoxicity and phototoxicity.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
Not applicable; contraindicated. No safe dose established. Increased volume of distribution and renal clearance in pregnancy would likely require dose escalation if used, but risk outweighs benefit.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
Cerinta (ceritinib) is a potent ALK inhibitor. Must monitor for GI toxicities (diarrhea, nausea, vomiting) and hepatotoxicity. Administer with food to reduce nausea. Avoid concurrent strong CYP3A4 inhibitors/inducers. Baseline and periodic LFTs, serum lipase, and glucose are required. May cause QTc prolongation; avoid in patients with baseline QTc >470 ms. Interstitial lung disease (ILD) is a rare but serious adverse effect; discontinue if ILD suspected.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take ceritinib exactly as prescribed, with food, at the same time each day.,Do not crush or split tablets; swallow whole.,Common side effects include diarrhea, nausea, vomiting, and abdominal pain; contact your doctor if severe or persistent.,Report any signs of liver problems (yellow skin/eyes, dark urine, severe fatigue) or pancreatitis (severe upper abdominal pain).,Avoid grapefruit juice, grapefruit, and Seville oranges during treatment.,Inform your doctor about all medications you take, including over-the-counter drugs and supplements.,Women of childbearing age must use effective contraception during treatment and for at least 2 weeks after the last dose.,Do not breastfeed while taking this medicine.,Monitor blood glucose levels regularly; report any symptoms of hyperglycemia (excessive thirst, frequent urination).,Avoid activities requiring alertness if you experience dizziness or fatigue.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CERINTA vs ADQUEY, answered by our medical review team.
CERINTA is a Oral contraceptive that works by Selective serotonin reuptake inhibitor (SSRI); enhances serotonergic neurotransmission by inhibiting serotonin reuptake at the presynaptic neuron.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CERINTA and ADQUEY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CERINTA is: 50 mg orally twice daily. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CERINTA and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CERINTA is classified as Category C. Cerinta is contraindicated in pregnancy. First trimester: High risk of neural tube defects and cardiac malformations. Second and third trimesters: Risk of oligohydramnios, fetal re. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.